HealthCare Pharmaceuticals Announces American Society of Clinical Oncology Presentation Of DKN-01 Clinical Study In Non-Small Cell Lung Cancer And First Patients Dosed In Clinical Study For DKK1+ Esophageal Cancer
6/2/2014 10:43:14 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--HealthCare Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing novel, targeted drugs for the treatment of cancer, today announced the presentation of data at the 50th Annual Meeting of the American Society for Clinical Oncology from the clinical development of its DKN-01 monoclonal antibody for the treatment of non-small cell lung cancer (NSCLC) and the dosing of its first patients in a clinical trial of DKN-01 for DKK1 positive (DKK1+) Esophageal Cancer (EC).
Help employers find you! Check out all the jobs and post your resume.
comments powered by